ReviewClinical and experimental nephrology2012
Luminex and antibody detection in kidney transplantation.
Review in Clinical and experimental nephrology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Clinical outcomes among renal transplant recipients with pre-transplant weakly reactive donor-specific antibodies.Clinical transplantation · 2014Trial
- Positive B cell flow cytometry crossmatch without detectable donor-specific antibodies: true or false reactivity?Frontiers in immunology · 2025Article
- Immunoassays and Mass Spectrometry for Determination of Protein Concentrations in Genetically Modified Crops.Journal of agricultural and food chemistry · 2024Review
- Innate-like self-reactive B cells infiltrate human renal allografts during transplant rejection.Nature communications · 2021Article
- Specific amino acid patterns define split specificities of HLA-B15 antigens enabling conversion from DNA-based typing to serological equivalents.Immunogenetics · 2020Article
- Effect of Preformed or De Novo Anti-HLA Antibodies on Function and Graft Survival in Kidney Transplant Recipients.Annals of transplantation · 2018Article
- Outcome after Desensitization in HLA or ABO-Incompatible Kidney Transplant Recipients: A Single Center Experience.PloS one · 2016Article
- Effects of complement activation on allograft injury.Current opinion in organ transplantation · 2015Review
- Human leukocyte antigens and alloimmunization in heart transplantation: an open debate.Journal of cardiovascular translational research · 2014Review
- Complement as a multifaceted modulator of kidney transplant injury.The Journal of clinical investigation · 2014Review
- Long-term outcomes of children after solid organ transplantation.Clinics (Sao Paulo, Brazil) · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Preformed anti-human leukocyte antigen (HLA) antibodies have a negative effect on kidney transplantation outcome with an increased rejection rate and reduction in survival. Posttransplantation production of donor-specific anti-HLA antibodies is indicative of an active immune response and risk of transplantation rejection. For many years the primary technique for anti-HLA antibody detection was complement-dependent cytotoxicity (CDC), which has been integrated by solid-phase assays as HLA antigen-coated bead methods (Luminex). This new technological approach has allowed identification of anti-HLA antibodies, not detectable using conventional CDC method, in patients awaiting kidney transplantation. Moreover, use of Luminex technology has enabled better definition of acceptable or unacceptable antigens favoring transplantation in highly immunized patients. However, there are still many unresolved issues, including the clinical relevance of antibodies detected with this system.
Indexed as
Identifiers
22552384What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.